title: Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents.
abstract: We retrospectively analyzed the outcomes of 175 consecutive patients admitted to our hospital between April 2004 and June 2014, and identified 42 (24%), 80 (46%), and 53 (30%) patients ≥ 80, 66-79, and ≤ 65 years old, respectively. The median progression-free survival (PFS) and overall survival (OS) of the ≥ 80, 66-79, and ≤ 65 years old groups were 19.1, 26.3, and 54.3 months, and 31.9, 54.8, and 83.8 months, respectively. Patients ≥ 80 but not ≤ 79 years old with ECOG performance score (PS) ≥ 3 and/or Charlson comorbidity index (CCI) ≥ 5 showed significantly shorter survival. ECOG PS and CCI predicted the treatment outcome of patients ≥ 80 but did not predict ≤ 79 years old.
authors.affiliation: a Division of Hematology/Oncology, Department of Medicine , Kameda Medical Center , Kamogawa-shi , Japan.
authors.forename: Kosei
authors.initials: K
authors.lastname: Matsue
authors.affiliation: b Department of Cardiology , University Medical Center Groninge , Groninge , The Netherlands.
authors.forename: Yuya
authors.initials: Y
authors.lastname: Matsue
authors.affiliation: a Division of Hematology/Oncology, Department of Medicine , Kameda Medical Center , Kamogawa-shi , Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Fujisawa
authors.affiliation: a Division of Hematology/Oncology, Department of Medicine , Kameda Medical Center , Kamogawa-shi , Japan.
authors.forename: Kota
authors.initials: K
authors.lastname: Fukumoto
authors.affiliation: a Division of Hematology/Oncology, Department of Medicine , Kameda Medical Center , Kamogawa-shi , Japan.
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Suehara
authors.affiliation: a Division of Hematology/Oncology, Department of Medicine , Kameda Medical Center , Kamogawa-shi , Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sugihara
authors.affiliation: a Division of Hematology/Oncology, Department of Medicine , Kameda Medical Center , Kamogawa-shi , Japan.
authors.forename: Masami
authors.initials: M
authors.lastname: Takeuchi
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers; D002869:Chromosome Aberrations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers
keywords: 80 years old; Age; comorbidity; multiple myeloma; performance status; survival